
Molbio Diagnostics' Rs 940 crore IPO was subscribed 70.26 times, with the QIB portion oversubscribed 186 times. Allotment is finalised on Thursday, August 13, and refunds begin Friday. Shares list on BSE…
Molbio Diagnostics' Rs 940 crore IPO was subscribed 70.26 times, with the QIB portion oversubscribed 186 times. Allotment is finalised on Thursday, August 13, and refunds begin Friday. Shares list on BSE and NSE on Monday, August 17. The grey market premium is around Rs 156, implying a listing gain of about 19 per cent over the Rs 807 issue price.

Investors can check allotment status on KFin Technologies, BSE, or NSE portals. Anchor investors, including World Bank's IFC and HDFC Mutual Fund, put in Rs 281 crore. IFC's Rs 20 crore investment marks its first Indian IPO anchor role in five years. Brokerages have given Subscribe ratings, citing reasonable valuations and growth plans.
The IPO frenzy is back, but retail investors should not mistake grey market premiums for certainty. The 70 times subscription and 19 per cent GMP look impressive, yet allotment odds are thin: small HNI investors have a 1.78 per cent chance. Chasing listing gains is speculation, not investing. Watch the first few trading sessions after August 17. If the stock holds above the issue price after a week, the optimism is justified. Otherwise, it is just another overhyped debut.
Sources (3): economictimes.indiatimes.com, livemint.com, businesstoday.in
This story was synthesised by AI from the 3 sources linked above.
Updated: this story now draws on 3 sources.